ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,700.30
-0.31%
S&P ASX All Technology
3,078.20
-0.47%
Brent Oil
83.895
2.16%
US Dollar vs AUD
1.51229
0.00%
Bitcoin
66,760.21
0.18%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NeuBase Therapeutics Inc (NBSE)

  7. NeuBase Therapeutics Inc (NBSE) News

NBSE

NeuBase Therapeutics (NBSE)

NeuBase Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NBSE
DateTimeSourceHeadlineSymbolCompany
04/06/202406:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
01/06/202406:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
23/05/202406:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
17/05/202400:07Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:NBSENeuBase Therapeutics Inc
14/05/202406:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
06/05/202421:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
06/04/202407:05GlobeNewswire Inc.NeuBase Therapeutics Announces Receipt of Notice from NasdaqNASDAQ:NBSENeuBase Therapeutics Inc
08/03/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
24/02/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
27/01/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
17/01/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/12/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/12/202322:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NBSENeuBase Therapeutics Inc
22/12/202322:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/11/202301:00GlobeNewswire Inc.Psychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNASDAQ:NBSENeuBase Therapeutics Inc
10/11/202308:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBSENeuBase Therapeutics Inc
07/11/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
07/11/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
20/10/202322:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
18/10/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
30/09/202306:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
21/09/202310:42Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
21/09/202307:28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
19/09/202306:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
19/09/202306:20Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
19/09/202306:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
14/09/202320:03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
13/09/202307:20Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
12/09/202307:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
08/09/202321:00GlobeNewswire Inc.NeuBase Therapeutics Issues Statement Regarding Filing By ShareholderNASDAQ:NBSENeuBase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NBSE

Your Recent History

COIN
ETHUSD
Ethereum
FX
AUDCAD
AUD vs CAD
ASX
WDC
Westfield
ASX
XJO
S&P ASX 200
ASX
XTO
S&P ASX 100
ASX
BHP
BHP
ASX
XMM
S&P ASX 300 Metals and M...
ASX
NCM
Newcrest Mining
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
NYSE
JPM
JP Morgan Chase
ASX
CBA
Commonwealth Bank Of Aus...
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
ASX
NAB
National Australia Bank
ASX
WBC
Westpac Banking
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved